Literature DB >> 20509151

Uptake of prenatal diagnostic testing and the effectiveness of prenatal screening for Down syndrome.

Alice M Jaques1, Veronica R Collins, Evelyne E Muggli, David J Amor, Ivan Francis, Leslie J Sheffield, Jane L Halliday.   

Abstract

OBJECTIVES: To map prenatal screening and diagnostic testing pathways in Victorian pregnant women during 2003 to 2004; measure the impact of prenatal diagnostic testing uptake on the effectiveness of prenatal screening for Down syndrome; and assess factors influencing uptake of diagnostic testing following screening.
METHODS: State-wide data collections of prenatal screening and diagnostic tests were linked to all Victorian births and pregnancy terminations for birth defects.
RESULTS: Overall, 52% of women had a prenatal test (65 692/126 305); screening (44.9%), diagnostic testing (3.9%), or both (3.2%). Uptake of diagnostic testing was 71.4% (2390/3349) after an increased risk screen result, and 2.5% (1381/54 286) after a low risk result. Variation in uptake of diagnostic testing reduced the effectiveness of the screening program by 11.2%: from 87.4% (sensitivity - 125/143) to 76.2% (prenatal diagnoses of Down syndrome - 109/143). In both the increased and low risk groups, uptake was influenced by absolute numerical risk, as well as by the change in numerical risk from a priori risk.
CONCLUSIONS: This comprehensive follow-up demonstrates clearly that numerical risk is being used to aid in decision making about confirmatory diagnostic testing. Collectively, these fundamental individual decisions will impact on the overall effectiveness of screening programmes for Down syndrome.

Entities:  

Mesh:

Year:  2010        PMID: 20509151     DOI: 10.1002/pd.2509

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  6 in total

Review 1.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

2.  A Cost-Effectiveness Analysis of Screening Strategies Involving Non-Invasive Prenatal Testing for Trisomy 21.

Authors:  Shuxian Wang; Kejun Liu; Huixia Yang; Jingmei Ma
Journal:  Front Public Health       Date:  2022-05-31

3.  Effect of enhanced information, values clarification, and removal of financial barriers on use of prenatal genetic testing: a randomized clinical trial.

Authors:  Miriam Kuppermann; Sherri Pena; Judith T Bishop; Sanae Nakagawa; Steven E Gregorich; Anita Sit; Juan Vargas; Aaron B Caughey; Susan Sykes; Lasha Pierce; Mary E Norton
Journal:  JAMA       Date:  2014-09-24       Impact factor: 56.272

4.  The impact of national prenatal screening on the time of diagnosis and outcome of pregnancies affected with common trisomies, a cohort study in the Northern Netherlands.

Authors:  Katelijne Bouman; Marian K Bakker; Erwin Birnie; Lies Ter Beek; Caterina M Bilardo; Irene M van Langen; Hermien E K de Walle
Journal:  BMC Pregnancy Childbirth       Date:  2017-01-05       Impact factor: 3.007

5.  A contingent model for cell-free DNA testing to detect fetal aneuploidy after first trimester combined screening.

Authors:  Carmen Cotarelo-Pérez; Raluca Oancea-Ionescu; Eloy Asenjo-de-la-Fuente; Dolores Ortega-de-Heredia; Patricia Soler-Ruiz; Pluvio Coronado-Martín; María Fenollar-Cortés
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-01-15

6.  Trial by Dutch laboratories for evaluation of non-invasive prenatal testing. Part I-clinical impact.

Authors:  Dick Oepkes; G C Lieve Page-Christiaens; Caroline J Bax; Mireille N Bekker; Catia M Bilardo; Elles M J Boon; G Heleen Schuring-Blom; Audrey B C Coumans; Brigitte H Faas; Robert-Jan H Galjaard; Attie T Go; Lidewij Henneman; Merryn V E Macville; Eva Pajkrt; Ron F Suijkerbuijk; Karin Huijsdens-van Amsterdam; Diane Van Opstal; E J Joanne Verweij; Marjan M Weiss; Erik A Sistermans
Journal:  Prenat Diagn       Date:  2016-11-15       Impact factor: 3.050

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.